CDK1 and non-small cell lung carcinoma: Tan et al. found that high expression of FOXD2-AS1 could promote the progression of non-small cell lung cancer through the Wnt/β-catenin signaling pathway [15], while Yang et al. found that FOXD2-AS1 could promote the progression of colon cancer by regulating the EMT and Notch signaling pathways [16], and Wang et al. also found that FOXD2-AS1 promoted the progression and proliferation of glioma cells through the FOXD2-AS1/miR-31/CDK1 pathway [26].